Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Ardelyx Inc. (NASDAQ:ARDX) Drug Thrives In Trials

Ardelyx Inc. (NASDAQ:ARDX)

Shares of Ardelyx Inc. (NASDAQ:ARDX) gained 36.11% in after-hours of trading, after the late-stage company said its experimental drug for irritable bowel syndrome met its primary endpoint. According to the drug developer, Tenapanor met the main goal of reducing abdominal pain and increasing bowel improvements.

IBS-C Treatment Opportunity

The positive clinical trial results could have a significant impact on the stock, especially after the Chief Executive Officer, Mike Raab claimed the results are a game changer for patients with IBS-C. Shares of Ardelyx are in dire need of a catalyst after its price edge lower after coming under pressure in May.  The stock is already down by more than 50% as it continues to trade at multi-year lows.

Ardelyx Inc. (NASDAQ:ARDX)

Investors’ confidence on the stock has taken a hit this year. However, the positive Tenapanor clinical trial results could be the catalyst to renew interest, given that the condition affects more than 11 million people across the United States.

“Based on tenapanor unique mechanism of action, which relies upon the inhibition of sodium absorption, and the exciting data reported today, tenapanor has the potential to be an important advancement and a new treatment option for patients suffering from IBS-C,” said William Chey, M.D., University of Michigan.

The clinical trial results indicate that Tenapanor has significant potential which increases the chances of Ardelyx Inc. (NASDAQ:ARDX) finding the ideal partner to bring it to market. Buoyed by the positive results, Ardelyx plans to submit, in the second half of next year, a New Drug Application (NDA) with the U.S Food and Drug Administration (FDA) for the treatment of IBS-C.

Ardelyx Restructuring

Separately, Ardelyx Inc. (NASDAQ:ARDX) completed a strategic review of its operations in the second quarter as it sought to position itself for multiple opportunities with its late-stage portfolio. The review process has resulted in the prioritization of resources to focus on upcoming milestones for late stage programs.  The company has also reduced its workforce by 28%.

Thanks to cost-saving initiatives, Ardelyx Inc. (NASDAQ:ARDX) remains on track to extend its operating runaway to the end of 2018. During the quarter, the company reported a net loss of (-$25.7) million or (-$0.54) cents a share, compared to a net loss of (-$28.6) million reported a year earlier.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARDX and receive breaking news on other hot stocks by signing up for our free newsletter!

Strongbridge Biopharma plc. (NASDAQ:SBBP) Rattles Investors

Strongbridge Biopharma plc. (NASDAQ:SBBP)

Strongbridge Biopharma plc. (NASDAQ:SBBP) shares fell 18.7% after the rare disease therapeutic developer announced the pricing of a share offering. The company has priced an underwritten public offering of 4 million ordinary shares at a price of $6.25 a share.

Strongbridge Biopharma plc. (NASDAQ:SBBP)

SBBP Share Offering

The commercial stage biopharmaceutical company has also granted underwriters a 30-day option to purchase an additional 600,000 ordinary shares. Strongbridge Biopharma plc. (NASDAQ:SBBP) expects gross proceeds of $25 million. The offerings should close on or about October 6, 2017, subject to satisfaction of customary closing conditions. Pricing of the offering $6.25 a share also did not go well with investors, as it represented a discount from the previous day closing price of $7.50 a share.

Wednesday’s sell-off pushed the stock to a key support level. However, Strongbridge Biopharma plc. (NASDAQ:SBBP) is still up by more than 100% for the year as it continues to trade in a strong uptrend.

Cash Burn Concerns

The price drop also came on growing concern over the company’s cash burn rate. Strongbridge Biopharma plc. began the year with $67 million in cash – of which it has already burned half. Investors fear that the company may be forced to offer more shares in the future in a bid to keep up with its spending.

Strongbridge Biopharma plc. (NASDAQ:SBBP) intends to use net proceeds from the underwritten public offering to expand commercial opportunities for Keveyis, its FDA approved product for primary periodic paralysis. Purchased from Taro Pharmaceuticals last year, the product generated $1.5 million in the second quarter.

Keveyis expansion could accelerate Strongbridge Biopharma plc. (NASDAQ:SBBP) cash burn over the next several quarters. The company has already indicated that it plans to spend part of the net proceeds from the offering for the development of Recorlev and veldoreotide. There are also plans to carry out acquisitions in addition to technologies that would accelerate topline growth.

Strongbridge Q2 Financial Results

Separately, Strongbridge Biopharma plc. (NASDAQ:SBBP) reported second quarter financial results that met Wall Street expectations. The company reported a net loss of (-$30.2) million or (-$0.34) a share which was in line with analyst’s expectations. Revenue in the quarter totaled $1.5 million compared to analysts’ expectations of $836,000.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SBBP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Gains on DMD Presentations

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) resurgence from all-time lows continued in Thursday’s trading session as its shares gained 21.9% to end the day at $2.23 a share. The rally followed the announcement that the clinical stage biopharmaceutical company will present results from a joint research collaboration with Sarepta Therapeutics Inc. (NASDAQ:SRPT).

Catabasis DMD Presentation

The presentation touches on a research collaboration for Duchene Muscular Dystrophy (DMD). The two companies are currently investigating CAT-1004, a known NF-Kb inhibitor, known to enhance myotube formation in-vitro.

In addition, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) will present results from an open-label extension of the MoveDMD trail, following five weeks of edasalonexent treatment in boys with DMD.

Shares of Catabasis closing above the $2 could be the catalyst needed to push the stock to the $2.50 mark, another key resistance level. CATB has underperformed the overall industry after losing more than 40% in market value since the start of the year. The clinical stage biopharmaceutical company is still trading in a downtrend even with the recent resurgence.

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)

Catabasis Q2 Earnings

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) bounce follows a second-quarter earnings report that showed substantial progress in trimming its net loss. For the three months ended June 30, 2017, the company reported a net loss of (-$7) million or (-$0.32) cents a share, down from a net loss of (-$9.4) million reported in Q2 2016.

Research and development expenses dropped to $4.5 million from $6.8 million a year ago, attributed to the completion of certain clinical activities. Headcount reductions led to a decline in General and Administrative expenses that totaled $2.4 million compared to $2.6 million as of Q2 2016. Catabasis Pharmaceuticals exited the quarter with cash and cash equivalent of $29.4 million compared to $31.8 million as of March 31, 2017.

“In the second quarter, we presented an important prespecified crossover analysis of data from boys with Duchenne in our Phase 2 edasalonexent trial. We are very excited to see improvements in the rate of decline of muscle function across multiple assessments in boys treated with edasalonexent for 12 weeks,” said CEO Jill C. Milne.

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is also working on CAT-5571 a potential oral treatment for cystic fibrosis.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CATB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Advaxis, Inc. (NASDAQ:ADXS) Stock Gaps Down Hard

Advaxis, Inc. (NASDAQ:ADXS)

Advaxis, Inc. (NASDAQ:ADXS) stock came under immense selling pressure as investors reacted to the company’s business update. The stock declined 19.68% as investors were rattled by a wider than expected net loss of (-$70.1) million.

Advaxis Stock Sell-Off

Tuesday’s sell-off saw Advaxis, Inc. (NASDAQ:ADXS) stock gap lower as it broke through a key support level to end the day at $5.48 a share. The stock has already recorded a new 52-week low as it continues to trade in a strong downtrend in a $5.40 – $7.40 trading range.

Advaxis, Inc. (NASDAQ:ADXS)
One month ADXS stock price chart

Advaxis, Inc. (NASDAQ:ADXS) sentiments on the Street have turned sour ever since Daniel J O’Connor resigned as CEO in June. The company is yet to appoint a permanent replacement – something that continues to spook investors. A wider than expected net loss is the latest headwind that continues raise concerns about its growth prospects.

The rate at which the company is burning cash is another point of concern. The company exited the third quarter with cash and cash equivalent of $89.4 million down from $115.3 million as of April 30, 2017. Chief Financial Officer, Sara Bonstein, has sought to quash investors’ concerns by reiterating they had a productive quarter even with a surge in net loss.

“The company had a productive third quarter while advancing the development of its core assets. There was increased spend in Q3 due to higher costs to support the regulatory filing of axalimogene filolisbac in Europe, and several one-time costs, which are not anticipated to recur,” Bonstein in a statement.

Growing Shareholder Value

In a bid to grow shareholder value, Actavis has embarked on a four franchise approach anchored in its LM technology. The platform is designed to effectively and safely target various cancers in multiple areas. To enhance the development of the platform the company plans to reprioritize programs for continued internal clinical development.

The growth strategy centers on four clear distinct franchises of HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy. Advaxis, Inc. (NASDAQ:ADXS) is preparing to file a marketing application submission with European regulators for axalimogene filolisbac a novel treatment for persistent or recurrent metastatic carcinoma of the cervix.

In addition, the company is collaborating with AstraZeneca plc. (ADR)(NYSE:AZN) on a Phase 2 combination trial with durvalumab in cervical and neck cancers.

“We continue to focus on building shareholder value and are committed to bringing clinically beneficial solutions to our patients and their families,” said Anthony Lombardo Interim CEO.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ADXS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OpGen Inc (NASDAQ:OPGN) Details New Tests For Predicting Antibiotic Susceptibility

OpGen Inc (NASDAQ:OPGN)

OpGen Inc (NASDAQ:OPGN) shares traded higher after the company presented the results of their Acuitas study. The Acuitas® AMR Gene Panel u5.47, and the Acuitas Lighthouse® are being developed for the prediction of antibiotic susceptibility. The stock was up by 1.33% in Friday’s trading session to end the week at $0.304 a share.

OpGen Inc (NASDAQ:OPGN)
One month OPGN stock price chart

Antibiotics Susceptibility Tests

OpGen Inc (NASDAQ:OPGN) presented at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance and included data based on the analysis of the Merck Study for Monitoring Antimicrobial Resistance Trends or SMART. OpGen Inc (NASDAQ:OPGN) is developing Acuitas AMR Gene Panel as a research use only semi-quantitative PCR for the detection of five bacterial pathogens in clinical isolates and urine specimens.

“We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development. The results from this study suggest the AMR Gene Panel can potentially aid in the rapid detection of resistance genes days ahead of antibiotic susceptibility testing,” said Terry Walker, Ph.D., OpGen Inc (NASDAQ:OPGN)’s senior vice president of research and development.

Last week’s rally did little to reverse a strong downtrend that has engulfed OpGen Shares. The stock is currently trading at the lower end of a tight $0.30-$0.33 trading range closing in on 52-week lows of $0.21 a share. The stock faces immediate resistance at the $0.38 mark, above which it could rise to highs of $0.40 a share.

Q2 Earnings Report

Separately, OpGen Inc (NASDAQ:OPGN) reported a net loss of (-$4.2) million for the three months ended June 30, 2017, compared to a net loss of (-$5.1) million reported last year. The company has embarked on a cost saving drive that seeks to trim operating expenses by 25% – 30%.

Revenue in the quarter fell to $0.7 million from $1.2 million in Q2 2016. Revenue for the first six months of the year came in at $1.5 million compared to $2.3 million for the six months ended June 30, 2016.

During the second quarter, OpGen Inc (NASDAQ:OPGN) completed a $10 million public offering of its common stock in which it generated $8.7 million in net proceeds. The funds are to be used to accelerate the development of the Acuitas Rapid Test and our Acuitas Lighthouse Knowledgebase. The company also entered into a global supply agreement with Thermo Fisher Scientific for the use of their technology to support the commercialization of rapid molecular products and informatics systems.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Pharmacyte Biotech Inc (OTCMKTS:PMCB) and Austrianova Sign New Terms

Pharmacyte Biotech Inc (OTCMKTS:PMCB)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has reached an agreement with Austrianova for the restructuring of certain agreements, pursuant to a previously agreed binding Term Sheet. Investors reacted to the news by sending the stock up.

Shares of Pharmacyte Biotech Inc (OTCMKTS:PMCB) are currently trading in a downtrend in a $0.05 – $0.06 trading range. The stock faces immediate support at the $0.05 mark below which it could register a new 2017 low. Its 52-week low is $0.02, registered last year.

Pharmacyte Biotech Inc (OTCMKTS:PMCB)
One month PMCB stock price chart

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a clinical stage biotechnology company, focused on the development of treatments for cancer and diabetes. The company also boasts of a Cell-in-a-Box technology acquired as part of a Binding Term Sheet with Austrianova.

Binding Term Sheet Terms

The restructuring of the binding Term Sheet, according to CEO Kenneth L Waggoner, should make it easier for the company to achieve its long term goals. Under the new terms, PharmaCyte will not make any milestone payments under the Asset Purchase agreement, Diabetes Licensing agreement, or the Cannabis Licensing Agreement.

The new terms also reduce the amount of royalty fees and sub-licensing royalty fees that the company will have to make. The new binding Term Sheet also provides PharmaCyte with a year of right-of-first-refusal should Austrianova choose to sell, assign, or transfer Cell-in-a-Box, Intellectual Property, or trade secrets.

“Not only has Austrianova made significant financial concessions, Austrianova has agreed to provide us with a vehicle by which we can acquire Cell-in-a-Box® and its Associated Technologies, including the manufacturing facility that will encapsulate the live cells required for our pancreatic cancer therapy and the other therapies we are developing,” said Mr. Waggoner.

Austrianova has also agreed not to solicit, negotiate, or entertain any inquiry regarding the sale of the Cell-in-a-Box and associated technologies. The Clinical stage biopharmaceutical company has also agreed to share with Austrianova 50% of any financial and non-financial consideration it receives under the asset purchase agreement. Pharmacyte Biotech Inc (OTCMKTS:PMCB) is also to pay Austrianova $150,000 over the next 6 months.

The chief executive officer expects the new binding Term Sheet to strengthen the partnership that has existed between Pharmacyte Biotech Inc (OTCMKTS:PMCB) and Austrianova since it bought the Cell-in-Box technology.

Pharmacyte Biotech Management Appointment

Separately, Pharmacyte Biotech Inc (OTCMKTS:PMCB) has confirmed the appointment of Linda S Sher as the company’s Chief Medical Officer. She joins the company as a professor of Clinical Surgery and Director of Clinical Research at the University Of Sothern California Keck School Of Medicine.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PMCB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Argos Therapeutics Inc (NASDAQ:ARGS) Stock Rises on Announcement

Argos Therapeutics Inc (NASDAQ:ARGS)

Shares of Argos Therapeutics Inc (NASDAQ:ARGS) rallied 12.65% after the company confirmed the dosing of the first HIV patient with AGS-004 dendritic cell therapy. The Phase 2 HIV eradication trial is being conducted in partnership with the University of North Carolina.

ARGS Stock Performance

The patient dosing marks the first time that an HIV patient has received a therapy utilizing RNA antigens from his latent lateral reservoir. The news did little to reverse the direction of ARGS stock as it continues to languish around all-time lows.

The stock is currently trading in a tight $0.21 – $0.25 per share range. Argos Therapeutics Inc (NASDAQ:ARGS) has underperformed the overall industry having shed more than 80% in market value since the start of the year. It awaits to be seen if the HIV trial is the catalyst that will help push the stock up from the current trading levels.

Argos Therapeutics Inc (NASDAQ:ARGS)
One month ARGS stock price chart

HIV Trial

The use of the RNA antigens from the patient’s latent reservoir was prompted by the fact the latent reservoir is where the HIV virus is most dominant, hidden from attack by the immune system. Current treatments agents have struggled to target the HIV virus in the reservoir rendering them inefficient.

The ongoing trial seeks to test whether boosting antiviral immunity with AGS-004, known to stimulate T-cells that attack HIV infected cells, will help expose the virus to the immune system to facilitate their eradication. According to Argos Therapeutics Inc. (NASDAQ:ARGS), the isolation of specific viral antigens from patients own could enable more focused immune system attack on the HIV virus.

“We believe that the new manufacturing process may allow AGS-004 to generate immune responses that are much better matched to the viral variants that will emerge during latency reversal with vorinostat treatment and, therefore, maximize the opportunity for viral clearance,” said Charles Nicolette, Chief Scientific Officer of Argos.

Argos Therapeutics Inc (NASDAQ:ARGS) has already enrolled four patients who will receive the AGS-004 manufactured using RNA antigens derived from infectious plasma. Results from ongoing Phase 2 eradication trial continues to be well tolerated.

Argos Therapeutics Inc (NASDAQ:ARGS) is funding the AGS-004 trial with finances provided by the National Institute of Health and the National Institute of Allergy and Infectious Diseases as well as Collaboratory of Research for Aids Eradication.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Why Financial Results for Celsion Corporation (NASDAQ:CLSN) Made No Waves

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) is a nano-cap biotechnology firm based in Lawrenceville, NJ. Celsion develops cancer treatments. These treatments include directed chemotherapies, DNA-medicated immunotherapy, and RNA-based therapies.

This morning Celsion Corporation (NASDAQ:CLSN) released 2016 financial results. In general, they met expectations and CLSN shares are trading flat in response. Celsion reported a net loss of $22.1 million, or $0.85 per share, compared to a net loss of $22.5 million, or $1.03 per share, in 2015. Operating expenses were $21.1 million in 2016 compared to $21.3 million in 2015. This decrease was primarily due to lower general and administrative expenses and clinical supply costs offset by higher clinical development costs for the Phase 3 OPTIMA Study. Research and development (R&D) costs were constant at $14.6 million in 2016 and 2015.

Celsion Corporation (NASDAQ:CLSN) investors have not had it easy. CLSN shares are down 80% for the year and 4.6% YTD. Still, two analysts continue to rate CLSN shares as a “Strong Buy” and one rates the stock a “Buy”. This could be in anticipation of a successful result in their Phase 3 OPTIMA study which is designed to evaluate the efficacy of ThermoDox – their lead product candidate. ThermoDox is being used I conjunction with standardized RFA in patients with liver cancer. 550 patients in 75 global locations are participating. The primary endpoint is overall survival. The targeted outcome is a 33% increase in overall survival rates. Thermodox is also in a Phase 2 study for the treatment of recurrent chest wall breast cancer.

Celsion Pipeline:

Shareholder Landscape

Aside from the ever-present, expected biotech programmatical challenges, Celsion Corporation (NASDAQ:CLSN) continues to dilute shareholder equity which has propelled shares downward for years. On February 15, 2017 Celsion announced a public offering with expected gross proceeds of $5 million. That announcement sent shares tumbling over 30%. This has continued the trend to issue shares over the years. In 2011 the number of outstanding shares stood at 4.65 million. In the following years the number of outstanding shares grew to 7.73 million, 13.54 million, 18.47 million, and, in 2015, 21.81 million.

Still, traders are active in CLSN. The average daily volume is 2.41 million shares and yesterday over 6.2 million shares traded hands. Insiders are also buying up CLSN. Director Alberto Martinez Jr. purchased 45,000 shares of CLSN worth $9,450 in February. In October, Chairman, President, and CEO Michael Tardugno bought 10,000 shares of CLSN on the open market.

3/16/2017
Ticker Symbol CLSN
Last Price a/o 2:53 PM EST  $                      1.53
Average Volume                2,410,000
Market Cap (mlns)  $                    11.29
Sales (mlns) $0.50
Shares Outstanding (mlns) 38.93
Share Float (mlns) 29.23
Shortable Yes
Optionable Yes
Inside Ownership 1.00%
Short Float 2.02%
Short Interest Ratio 0.25
Quarterly Return -56.39%
YTD Return -4.57%
Year Return -79.29%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Arena Pharmaceuticlas, Inc. (NASDAQ:ARNA) Gets Financial Boost from Belviq

Arena Pharmaceuticlas, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are up over 20% in pre-market trading. Trading volumes are heavy. ARNA has a listed average daily volume of just over 1.5 million shares but already in the pre-market over 1 million shares have traded hands and have hit a inter-day high of $1.70. The increased market action comes after the San Diego, CA-based company posted Q4 and full year earnings after the close yesterday.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a biopharmaceutical company that develops small molecule drugs. Currently Arena has three drugs in its pipeline:

  • Ralinepag – an oral IP receptor for the treatment of pulmonary arterial hypertension.
  • Etrasimod – an oral receptor modulator for the treatment of multiple auto-immune diseases.
  • APD371 – an oral receptor for the treatment of pain in people afflicted with Crohn’s disease.

Arena also has two collaboration efforts:

  • Axovant Sciences Ltd. – marketing and supply agreement for Nelotanserin, a drug for the treatment of people with either dementia or Lewy bodies. Phase 2 clinical trials expected in 2017.
  • Beohringer Ingelheim – research and licensing agreement to identify drug candidates suitable for continued research and development of drug candidates targeting psychiatric diseases.
2016 Financials and History

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revenues were reported at $124 million. 21% ($26.3 million) of those revenues were from Belviq product sales and 58% ($72.1 million) were from Belviq upfront payments. Research and development expenses were $66.4 million. Net loss was $22.9 million or $0.09/share. Net income attributable to shareholders on a diluted basis comes in at -$0.16/share. Analysts were expecting revenues of $15.6 million and an EPS loss of -$0.08. Net product sale are being reported at $26.4 million.

In 2015, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted an EPS loss of -$0.45 which was a larger figure than the 2014 EPS loss of -$0.28. Sales for 2014 and 2015 were relatively flat. In 2014 sales were posted at $37 million followed the next year by a figure of $38.3 million.

Four firms follow Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Two analysts rate ARNA shares as a “Strong Buy” and the other two rate the shares as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.